During the past decade, Kanagawa Cancer Center conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on
average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Brightline-2: A Study to Test Whether BI 907828 Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
2022-11-25
2026-11-25
Recruiting
130
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Kanagawa Cancer Center
According to Clinical.Site data, the most researched conditions in "Kanagawa Cancer Center" are
"Biliary Tract Cancer" (1 trials), "Bladder Cancer" (1 trials), "Head and Neck Squamous Cell Carcinoma (HNSCC)" (1 trials), "Lung Neoplasms" (1 trials) and "Neoplasms" (1 trials). Many other conditions were trialed in "Kanagawa Cancer Center" in a lesser frequency.
Clinical Trials Intervention Types at Kanagawa Cancer Center
Most popular intervention types in "Kanagawa Cancer Center" are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Carboplatin" (2 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody" (1 trials), "BI 754091" (1 trials) and "BI 754111" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Kanagawa Cancer Center
The vast majority of trials in "Kanagawa Cancer Center" are
5 trials for "All" genders.
Clinical Trials Status at Kanagawa Cancer Center
Currently, there are NaN active trials in "Kanagawa Cancer Center".
undefined are not yet recruiting,
2 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in Kanagawa Cancer Center,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Kanagawa Cancer Center, 1 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".